Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.
On Feb. 16, 2009, Charla Nash visited the home of her longtime friend, Sandra Herold, like she’d done many times before. Unfortunately, the visit was anything but normal. Sandra and her husband, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results